Now showing items 1-4 of 4

    • BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. 

      Tacconi, EM; Lai, X; Folio, C; Porru, M; Zonderland, G; Badie, S; Michl, J; Sechi, I; Rogier, M; Matía García, V; Batra, AS; Rueda, OM; Bouwman, P; Jonkers, J; Ryan, A; Reina-San-Martin, B; Hui, J; Tang, N; Bruna, A; Biroccio, A; Tarsounas, M (2017-10)
      Maintenance of genome integrity requires the functional interplay between Fanconi anemia (FA) and homologous recombination (HR) repair pathways. Endogenous acetaldehyde, a product of cellular metabolism, is a potent source ...
    • Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. 

      Holme, H; Gulati, A; Brough, R; Fleuren, EDG; Bajrami, I; Campbell, J; Chong, IY; Costa-Cabral, S; Elliott, R; Fenton, T; Frankum, J; Jones, SE; Menon, M; Miller, R; Pemberton, HN; Postel-Vinay, S; Rafiq, R; Selfe, JL; von Kriegsheim, A; Munoz, AG; Rodriguez, J; Shipley, J; van der Graaf, WTA; Williamson, CT; Ryan, CJ; Pettitt, S; Ashworth, A; Strauss, SJ; Lord, CJ (2018-07-13)
      Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic loss of heterozygosity (LOH) ...
    • Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma. 

      Bhide, SA; Thway, K; Lee, J; Wong, K; Clarke, P; Newbold, KL; Nutting, CM; Harrington, KJ (2016-09)
      The aim of this study was to investigate if defective repair of DNA double-strand break (DSB) in head and neck squamous cell carcinoma (HNSCC) could be used as an early predictor of treatment response.Tumour biopsy 24-36 h ...
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. 

      Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; Proszek, P; Hubank, M; Dowsett, M; Dodson, A; Daley, F; Kriplani, D; Gevensleben, H; Davies, HR; Degasperi, A; Roylance, R; Chan, S; Tutt, A; Skene, A; Evans, A; Bliss, JM; Nik-Zainal, S; Turner, NC (2020-05-29)
      Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ...